About Us

Stitch Team

Jonathan D. Glass, MD

Chief Medical Officer

Dr. Glass is a Professor of Neurology and Pathology at Emory University, where he directs the Emory Amyotrophic Lateral Sclerosis (ALS) Center. A world-renowned clinician-scientist, Dr. Glass brings decades of experience in ALS clinical research, trial design, and biomarker discovery. At Stitch, he leads clinical strategy and development of antisense oligonucleotide (ASO) therapeutics, overseeing the translation of preclinical discoveries into patient-ready interventions. His work focuses on embedding theranostic biomarkers into early-phase clinical trials to measure target engagement, disease modification, and treatment response in individuals with TDP-43–related ALS. Recognized among “America’s Top Doctors,” Dr. Glass has played a pivotal role in defining ALS subtypes, identifying genetic and molecular determinants of disease progression.

Nicholas T. Seyfried, PhD

Chief Scientific Officer

Dr. Seyfried is a Professor of Biochemistry and Neurology at Emory University School of Medicine, where he also serves as Associate Director of the Emory Center for Neurodegenerative Disease. An internationally recognized leader in quantitative mass spectrometry–based proteomics, Dr. Seyfried has pioneered large-scale approaches to define the molecular architecture of neurodegenerative diseases. At Stitch, he leads scientific strategy across proteomics-driven drug discovery, biomarker development, and patient subtyping, integrating multi-omic data to guide the design and evaluation of antisense oligonucleotide (ASO) therapeutics. His work focuses on identifying proteomic and transcriptomic signatures of TDP-43 loss-of-function that can serve as pharmacodynamic biomarkers of ASO response and molecular correction. Dr. Seyfried has co-founded multiple biotechnology ventures, including Stitch, ArcProteomics and Emtherapro. Dr. Seyfried earned his D.Phil in Biochemistry from the University of Oxford and has authored more than 250 publications advancing systems-level understanding of Alzheimer’s disease, ALS, and related proteinopathies. His leadership at Stitch brings together cutting-edge proteomics, translational biology, and precision medicine to accelerate the discovery of therapeutics that repair RNA dysfunction and restore neuronal health.

Zachary T. McEachin, PhD

Chief Technology Officer

Dr. Zachary T. McEachin is an Assistant Professor in the Department of Human Genetics at Emory University School of Medicine. Trained as a biomedical engineer, Dr. McEachin combines deep expertise in RNA biology, antisense oligonucleotide (ASO) design, and therapeutic engineering to advance Stitch’s platform for correcting cryptic exon splicing in TDP-43–related ALS and frontotemporal dementia (FTD). At Stitch, he leads technology development efforts spanning ASO chemistry optimization, molecular screening, and preclinical validation. His work bridges computational design, cellular modeling, and in vivo delivery strategies to enhance ASO efficacy and specificity. Dr. McEachin earned his PhD in Biomedical Engineering from the Georgia Institute of Technology, where he trained at the intersection of molecular neuroscience and bioengineering. His academic research, supported by the National Institute of Neurological Disorders and Stroke (NINDS), investigates the mechanisms of chimeric dipeptide repeat production and toxicity in C9orf72-linked ALS and FTD.

Kiran Pandey, PhD

Advisor, Partnerships and Commercial Strategy

Dr. Pandey provides strategic guidance on business development, partnerships, and commercialization of therapeutics and biomarker-driven precision medicine programs. He brings over a decade of experience spanning healthcare, biotechnology, and strategy consulting. Before joining Stitch, Dr. Pandey served as CEO of Emtherapro, where he led efforts to harness multi-omics platforms for precision medicine in neurodegenerative diseases. He has also held leadership roles in product development, marketing, innovation, and analytics at Lumeris, GE Healthcare, and McKinsey & Company. With a strong background in both science and business, Dr. Pandey bridges early-stage discovery and commercial strategy to position Stitch’s ASO pipeline for clinical and market success. He holds a PhD in biomedical engineering at the University of Michigan and continues to advise biotechnology ventures through Arc BioVentures.

Ben Vollrath, PhD

Advisor, Therapeutic development and Diagnostics

Dr. Vollrath is a seasoned life-science executive and biotech entrepreneur with extensive experience in, therapeutic development and diagnostic platforms. He currently serves as a consultant for Stitch, advising on strategic development of antisense oligonucleotide (ASO) therapeutics and biomarker integration for TDP-43–related neurodegenerative diseases. Prior to his current role, he served as Chief Operating Officer at Amprion, Inc. where he oversaw strategy and operations in neurodegenerative-disease biomarker development. He previously held leadership positions including CEO of Xetrios Therapeutics and co-founded multiple biotech companies that achieved successful exits. Dr. Vollrath is credited with over 40 patents or patent applications and a track record of translating early-stage science into clinical or commercial platforms. He holds a PhD from University of Tübingen and is focused on driving next-generation therapeutic development.